Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BJDX

Bluejay Diagnostics Inc

1.02

Aug 17 • 3:59 PM ET -0.03 (-2.86%)

1.02

Aftermarket • 7:44 PM ET 0.00 (0.00%)

Healthcare Medical Devices USA Nano NASD

Aug 13, 12:15 PMBluejay Diagnostics files Q2 2026 results, confirms completion of 750-patient SYMON-II pivotal study

Peers: AEMD IVF VTAK INBS NUWE TNON XAIR AMIX HSCS NXL

Scroll to Statements

Index	-
Market Cap	4.56M
Enterprise Value	-4.96M
Income	-7.27M
Sales	0.00M
Book/sh	4.75
Cash/sh	2.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Nov 10, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.21
P/C	0.47
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.64
Current Ratio	4.64
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-9.49
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	89.89% 65.04%
Sales past 3/5Y	- -
EPS Y/Y TTM	93.91%
Sales Y/Y TTM	-
EPS Q/Q	80.19%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-155.21% -

Insider Own	9.50%
Insider Trans	27.53%
Inst Own	8.35%
Inst Trans	2.01%
ROA	-81.07%
ROE	-98.89%
ROIC	-77.21%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.33%
SMA50	-51.11%
SMA200	-64.47%
Trades

Shs Outstand	4.47M
Shs Float	4.04M
Short Float	0.42%
Short Ratio	0.00
Short Interest	0.02M
52W High	16.68 -93.88%
52W Low	0.83 22.89%
Volatility	9.56% 12.89%
ATR (14)	0.21
RSI (14)	40.21
Beta	0.97
Rel Volume	0.07
Avg Volume	5.89M
Volume	386,890

Perf Week	3.32%
Perf Month	-29.66%
Perf Quarter	-38.92%
Perf Half Y	-61.80%
Perf YTD	-61.78%
Perf Year	-81.25%
Perf 3Y	-99.99%
Perf 5Y	-
Perf 10Y	-
Recom	3.00
Target Price	51200.00
Prev Close	1.05
Price	1.02
Change %	-2.86%

Aug-13-26 06:00AM	Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization (GlobeNewswire)
Jul-21-26 06:30AM	Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study (GlobeNewswire)
Jun-05-26 08:13PM	Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -9.43% +8.96%
Jun-02-26 12:19PM	Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +100.00%
06:30AM	Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership (GlobeNewswire)
04:01PM	Loading…
May-07-26 04:01PM	Bluejay Diagnostics Provides First Quarter 2026 Corporate Update (GlobeNewswire) -5.49%
Apr-07-26 06:30AM	Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial (GlobeNewswire)
Mar-12-26 06:30AM	Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting (GlobeNewswire)
Mar-06-26 06:30AM	Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook (GlobeNewswire)
Feb-20-26 06:30AM	Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised (GlobeNewswire)
Feb-17-26 06:30AM	Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON II Study and Advances Manufacturing Readiness into 2026 (GlobeNewswire)
Jan-27-26 08:00AM	Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split (GlobeNewswire)
Dec-29-25 07:00AM	Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production (GlobeNewswire)
Nov-10-25 07:30AM	Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships (GlobeNewswire)
Oct-10-25 05:16PM	Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.66%
03:15PM	Loading…
Oct-09-25 03:15PM	Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +75.40%
06:30AM	Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform (GlobeNewswire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +34.29%
Aug-07-25 06:30PM	Bluejay Diagnostics Provides Second Quarter Business and Corporate Update (GlobeNewswire)
Jun-03-25 04:05PM	Bluejay Diagnostics Provides Mid-Year Business and Corporate Update (GlobeNewswire)
Apr-15-25 07:00AM	Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting (GlobeNewswire)
Apr-07-25 05:21PM	Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds (GlobeNewswire) +112.46% -60.67%
Nov-13-24 05:10PM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) -28.85%
Jun-28-24 11:32AM	Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering (GlobeNewswire) -6.77%
Jun-27-24 08:58AM	Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering (GlobeNewswire) -53.99%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 08:00AM	SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients (GlobeNewswire) -40.73%
Jun-17-24 08:00AM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) -20.43%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Mar-28-24 11:53PM	BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023 (InvestorPlace)
05:58PM	Loading…
Jan-02-24 05:58PM	Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering (GlobeNewswire)
Dec-28-23 08:00AM	Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering (GlobeNewswire) -32.48%
Dec-27-23 09:00AM	Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) (GlobeNewswire) -32.50%
Nov-09-23 04:05PM	Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results (GlobeNewswire) +5.71%
Aug-28-23 07:59AM	BJDX: FDA Meeting Confirms Pathway (Zacks)
Aug-25-23 08:00AM	Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -18.63%
Aug-16-23 07:00AM	Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-10-23 04:05PM	Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-24-23 08:30AM	Will Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely? (Simply Wall St.) +42.36%
Jul-21-23 07:00AM	Bluejay Diagnostics Announces Reverse Stock Split (GlobeNewswire) +16.31%
May-31-23 06:36AM	BJDX: Orchestrating a New Testing Standard (Zacks Small Cap Research) +22.94%
May-19-23 07:00AM	Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy (GlobeNewswire)
May-10-23 07:30AM	Bluejay Diagnostics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-20-23 04:15PM	Bluejay Diagnostics Reports 2022 Financial Results (GlobeNewswire) -16.40%
Feb-16-23 08:00AM	Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America (GlobeNewswire) +8.75%
Nov-13-22 08:01AM	Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k (Simply Wall St.)
Nov-09-22 08:00AM	Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire) -8.03%
Aug-30-22 04:05PM	Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 06:09AM	Here's Why We're Watching Bluejay Diagnostics' (NASDAQ:BJDX) Cash Burn Situation (Simply Wall St.)
Aug-16-22 07:30AM	Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure (GlobeNewswire)
Jul-27-22 07:30AM	Positive Clinical Results for Bluejays Symphony IL-6 Test Presented at AACC 2022 (GlobeNewswire) -17.73%
Jul-26-22 04:30PM	Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results (GlobeNewswire) +13.25%
Jul-06-22 07:30AM	Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test (GlobeNewswire) +7.48%
Jun-09-22 07:30AM	Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test (GlobeNewswire) +26.36%
May-05-22 11:21AM	As Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gains 41%, insiders who bought last year may be wishing they had bet higher (Simply Wall St.) -5.67%
Apr-20-22 04:10PM	Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-28-22 07:00AM	Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance (GlobeNewswire)
Mar-24-22 07:00AM	Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer (GlobeNewswire) -6.87%
Mar-17-22 06:53AM	Companies Like Bluejay Diagnostics (NASDAQ:BJDX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-10-22 07:00AM	Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.51%
Jan-31-22 07:00AM	Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA (GlobeNewswire) +5.77%
Jan-13-22 11:29AM	Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care (GlobeNewswire)
Jan-11-22 04:19PM	10 Low-Float Penny Stocks for Steel-Gutted Investors (InvestorPlace)
Jan-05-22 08:15AM	Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor (GlobeNewswire)
Dec-16-21 09:11AM	Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Dec-07-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-10-21 08:15AM	Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering (GlobeNewswire)

Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally invasive point-of-care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focuses on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Indranil Dey on March 20, 2015 and is headquartered in Acton, MA.

Principal FinancialMr. Indranil Dey

Chief Commercial OfficerMr. Kevin Vance

Ph.D.Mr. Mark W. Feinberg M.D.

Chief Medical AdvisorDr. Mark W. Feinberg M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRT FINANCIAL LP	10% Owner	Jul 09 '26	Buy	1.51	64,047	96,711	126,993	Jul 13 03:14 PM
HRT FINANCIAL LP	10% Owner	Jul 10 '26	Sale	1.40	34,938	48,913	92,055	Jul 13 03:14 PM
Wurth Douglas Clark	Director	Mar 14 '26	Buy	2.00	12,500	25,000	12,608	May 18 05:21 PM
Dey Indranil	President and CEO	Mar 14 '26	Buy	2.00	12,500	25,000	12,522	May 18 05:20 PM
CHASE DONALD R	Director	Mar 14 '26	Buy	2.00	12,500	25,000	12,525	May 18 05:20 PM
ZEIDMAN FRED S	Director	Mar 14 '26	Buy	2.00	12,500	25,000	12,500	May 18 05:19 PM
Dey Svetlana	Director	Mar 14 '26	Buy	2.00	12,500	25,000	12,501	May 18 05:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BJDX

Bluejay Diagnostics Inc

Upgrade your Finviz experience